NanoVibronix, Inc., (NASDAQ: NAOV) shares are in rally mode, holding a gain of 61% at press time. The jump came after NAOV announced that it intends to enter the Over-the-Counter (OTC) pain relief market with PainShield RELIEF™, a non-prescription ultrasound therapy device that delivers fast pain relief resulting from nerve and soft tissue damage. Indeed, investors responded well to the news, sending not only the stock substantially higher but on trading volume that is roughly 15X its average pace. The attraction to NAOV also brings attention to companies already in the multi-billion dollar market, especially to those with marketing approvals. SANUWAVE (OTC: SNWV) is one of them.
Thus, while NAOV was the star of the day in the sector, the residual opportunities could be just as lucrative to SANUWAVE, which holds an exclusive worldwide license agreement to market NanoVibronix’s other best-in-class asset, its surface acoustic wave ultrasound technology targeting the wound care market, WoundShield®. That agreement provides SNWV exclusive worldwide license and sales rights for NanoVibronix’s patch-based therapeutic ultrasound technology device. It’s a unique device to say the least, facilitating tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. Marketing that product, which SNWV is in the process of doing, brings similar revenue-generating opportunities to SNWV. Hence, the markets may have missed the connection on Monday, keeping this under-the-radar trade intact.
SNWV intends to follow a similar course of marketing, intending to make WoundShield® available to the massive pain relief treatment. It adds to its dermaPACE® and UltraMIST® shockwave lineup, and will capitalize on additional market opportunities and add new revenue streams. Better still, SNWV is in the process of creating those streams now, seeking regulatory approval of WoundShield® in Europe and the United States.
By the way, SANUWAVE has never shied away about being bullish on its prospects.
Bullish Shockwave Markets
In fact, SNWV is decidedly bullish on the revenue-generating opportunities inherent to its WoundShield® license. Commenting on the agreement earlier this year, Kevin A. Richardson II, Chairman of the Board and CEO of SANUWAVE, said, “It is one of those great partnerships where our organization offers strong commercialization and sales capabilities and a complementary energy-based wound care treatment system in the dermaPACE® System. NanoVibronix’s expertise in surface acoustic wave ultrasound technology development is unmatched, and we are very happy to have the responsibility to grow a high-quality product that has key benefits.”
NanoVibronix also sees the agreement as a win-win proposition. Brian Murphy, Chief executive Officer of NanoVibronix, said, “By leveraging the strength of SANUWAVE’s commercial organization, we’re able to focus on continued innovation in the surface acoustic wave ultrasound technology area. Together, I am hopeful that we can offer wound care professionals another high-quality treatment modality that can be applied to diabetic foot ulcers in between dermaPACE® System treatments. We look forward to working with SANUWAVE now and in the future.”
The NanoVibronix may have brought attention to itself today, but it’s likely investors will connect the dots leading back to SANUWAVE. After all, there has been plenty of validation for the sector.
Accretive Value In A Valued Sector
AbbVie (NYSE: ABBV) made a substantial move earlier this year to acquire Soliton (NASDAQ: SOLY) for $550 million. While the news was excellent, it wasn’t enough for SOLY shareholders, which felt the bid undervalued its assets. In either case, the more than half-billion-dollar purchase did validate the value intrinsic to the shockwave therapy sector. Moreover, it set the price tag high for those wanting these assets.
And that’s potentially excellent news for SANUWAVE, which knows the sector well with a stable of best-in-class products of its own. Arguments can be made that SNWVs asset portfolio is more substantial than SOLY’s, and few will dispute that point. If they point to share price as a point of inferiority, current levels result from delinquent filings to the SEC, which SNGX is expected to complete soon followed by a planned uplist to a more senior NASDAQ exchange.
SANUWAVE Asset Portfolio Stronger Than SOLY
Indeed, ABBV helped change the narrative on the value of shockwave technology. And while they purchased SOLY, which has one device, know that SNWV already has TWO FDA-cleared shockwave technology devices in the market.
And not only are its devices already commercialized, but they also drove record-setting revenue in its latest Q-report, earned an additional 11 patients in the past fifteen months, and extended its reach by developing several international markets. Considering those advantages compared to a non-revenue generating SOLY device, SANUWAVE’s value could soar once investors recognize that while the ABBV deal might be priced right for Soliton, SANUWAVE can be worth substantially more.
Now, with NanoVibronix bringing attention back to the sector, SNWV could be positioned to surge in sympathy. Remember, the massive rally in NAOV resulted from its other shockwave asset. Hence, SNWV is again in the right place at the right time.
Value Could Soar After Filings
And its consolidation in a tight trading range may be exposing a compelling value opportunity. However, after they get filings current, expect the deals accrued over the past six months to profoundly impact its share price. In fact, getting those done is likely the milestone investors are waiting for.
Once that happens, AbbVie’s bid to set a high valuation bar for companies in the shockwave sector, along with interest given to this morning’s NanoVibronix deal, puts SNWV in an excellent spot to earn a more appropriate valuation for its business and assets. Further, with proof that companies are willing to pay a massive price for shockwave technology, as well as to bid up shares for others exploiting the enormous market opportunities, expect a compliant SNWV share price to surge.
Best of all, with SNWV only a report away from being compliant, gains could come sooner rather than later.
Disclaimers: Hawk Point Media is responsible for the production and distribution of this content. Hawk Point Media is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by Hawk Point Media is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall Hawk Point Media be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Hawk Point Media, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Hawk Point Media was compensated up to five-thousand-dollars by a third-party to research, prepare, and syndicate written and visual content about Gourmet Provisions International Corp. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, Hawk Point Media, its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found by clicking HERE.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
Company Name: Hawk Point Media
Contact Person: Ken Lawrence
City: Miami Beach
Country: United States